NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.3200
+0.0300 (+0.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.2900
Open3.3200
Bid3.3000 x 2900
Ask3.3800 x 1000
Day's Range3.2500 - 3.3800
52 Week Range2.3400 - 8.9000
Volume225,815
Avg. Volume577,148
Market Cap29.377M
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

    At a workshop held January 22, 2020 in Landshut by the Krankenhaus Achdorf, in cooperation with Berlin-Chemie and Neovasc, Dr. Stylianos Pyxaras presented the Reducer as a new treatment option for chronic angina. “We are encouraged by the growing use and satisfaction of physicians with the outcomes of the Reducer Therapy for their patients,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations in Germany
    Newsfile

    Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

    Vancouver, British Columbia--(Newsfile Corp. - January 22, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ ("Reducer") was featured in three presentations across Germany this month.The presentations included:At the 20th Cardiology Symposium, held January 11, 2020 in Berlin, ...

  • GlobeNewswire

    Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting

    Neovasc Provides Corporate Update Vancouver, BC, Jan. 21, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the.

  • GlobeNewswire

    Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

    VANCOUVER, Jan. 15, 2020 -- via NEWMEDIAWIRE – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter.

  • Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer(TM)
    Newsfile

    Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer(TM)

    Vancouver, British Columbia--(Newsfile Corp. - January 15, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application ("PMA") from the U.S. Food and Drug Administration ("FDA") for its Neovasc ...

  • GlobeNewswire

    Neovasc Inc. Investor Update

    “We closed 2019 by doing what we said we would do, when we said we would do it,” said Fred Colen, President and CEO of Neovasc. Thus far approximately 1,300 patients have received the device and results have been encouraging, demonstrating effectiveness in treating refractory angina with a strong safety profile.

  • Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market
    Newsfile

    Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, British Columbia--(Newsfile Corp. - January 6, 2020) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units ("Series A Units") and 1,241,490 series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series ...

  • GlobeNewswire

    Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, Canada, Jan. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units (“Series A Units”) and series B units (“Series B Units” and together with the Series A Units, the “Units”) at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement  agent’s fees and estimated expenses of the Offering payable by the Company. Each Series A Unit will consist of one common share of the Company (each, a “Unit Share”) and one warrant (a “Warrant”) to purchase one common share.

  • Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market
    Newsfile

    Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, British Columbia--(Newsfile Corp. - January 2, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units ("Series A Units") and series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135 per ...

  • GlobeNewswire

    Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer™

    “This submission marks an important milestone in our effort to bring Reducer to the U.S. market, where it is estimated that there are up to 1.8 million patients with refractory angina,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)
    Newsfile

    Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)

    Vancouver, British Columbia--(Newsfile Corp. - December 31, 2019) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the submission of a Premarket Approval application ("PMA") to the U.S. Food and Drug Administration ("FDA") for its Neovasc Reducer™ ("Reducer") medical device for the treatment ...

  • Newsfile

    Neovasc Reducer(TM) Featured In National Geographic Magazine

    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a special issue titled: "The Future of Medicine" of National Graphic Magazine, published in December 2019. An ...

  • GlobeNewswire

    Neovasc Reducer™ Featured In National Geographic Magazine

    An image of the Reducer was accompanied by a case study of a patient who was implanted with the Reducer. Neovasc’s Medical Director, Prof. Shmuel Banai, MD, Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel, is also prominently featured.

  • Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019
    Newsfile

    Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and ...

  • GlobeNewswire

    Neovasc Named Finalist in Questex’s Fierce Innovation Awards LifeSciences Edition 2019

    Neovasc was recognized as a finalist in the category of Medical Device Innovation. Neovasc was selected as a finalist for its innovative Neovasc Reducer™ (the “Reducer”), a medical device developed for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.

  • GlobeNewswire

    Neovasc Reducer™ Featured In FOCUS Magazine

    Professor Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, explained to FOCUS readers in the supplement called “Medizinischer Fortschritt” how Reducer therapy helps patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of the Reducer therapy and highlighted that 75% of patients treated with Reducer feel better and experience less chest pain.

  • Neovasc Reducer(TM) Featured In FOCUS Magazine
    Newsfile

    Neovasc Reducer(TM) Featured In FOCUS Magazine

    Vancouver, British Columbia and Berlin, Germany--(Newsfile Corp. - November 26, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a supplement in the FOCUS Magazine, one of the three most widely circulated ...

  • Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola
    Newsfile

    Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

    Educational events featuring the Reducer hosted in Germany and Italy Vancouver, British Columbia, Coburg, Germany, and Cotignola, Italy--(Newsfile Corp. - November 22, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured during a program hosted ...

  • GlobeNewswire

    Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

    - Educational events featuring the Reducer hosted in Germany and Italy - VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, Nov. 22, 2019 -- via NEWMEDIAWIRE -- Neovasc,.

  • GlobeNewswire

    Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

    Anson Cheung, MD, Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia, and Principal Investigator for the Tiara Early Feasibility Study at St. Paul’s Hospital, Vancouver, BC, provided an update on the Tiara program as part of “Rapid fire - Latest updates from the world of TMVR,” a session focusing on early clinical outcomes of patients undergoing transcatheter mitral valve replacement and potential future device solutions. Outcome data was presented on 71 of the 80 high surgical risk patients who have been treated with TA Tiara in either the TIARA-I Early Feasibility Clinical Study, Compassionate Use cases, or the TIARA-II CE Mark Clinical Study.

  • Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019
    Newsfile

    Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 19, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal ("TF/TS") Tiara™ ("Tiara") System was featured today in a tutorial session at the PCR London Valves 2019 meeting, which is taking place November ...